Assegai Wins Big Settlement Against ABBOTT's Subsidiary

BEIJING, May 10, 2010 - On April 11, 2010, after a nearly two-year trial, the ten arbitration
cases with Beijing Un-Assegai Technical & Trade Co. Ltd. (hereinafter
referred to as "Assegai"), a leading distributor of clinical diagnostic
products in China, as claimant and U.S. Abbott Laboratories (Abbott U.S.;
NYSE: ABT) as respondent have been decided by the China International
Economic and Trade Arbitration Commission (CIETAC), which has recently
rendered the arbitral awards thereof. The advanced arbitral awards made by
three different arbitral tribunals held that Abbott U.S. broke and violated
the contracts with Assegai and thereby awarded Assegai a nearly one million
U.S. dollar settlement.

According to the arbitral awards, Assegai was the largest distributor of
Abbott medical diagnostic products in the North China area, on the basis of
the cooperation between Assegai and Abbott U.S. that started in 1999 soon
after Abbott U.S.'s entrance into the Chinese market. However, in November
2007, in the 9th successive year of this cooperation, Abbott U.S. cut off the
supply of reagents to Assegai without any justification, regardless of the
fact that Assegai had just purchased some very costly equipment from Abbott
U.S.

Mr. Yongfeng Cao, president of Assegai, commented: "We made a notable
contribution in helping Abbott's products to become the first-line products
in the Chinese market; in return, however, Abbott U.S. took advantage of its
market dominance and deprived us of our right to supply reagents to our
customers. By doing this, Abbott U.S. violated our right to property
ownership and use, which led to losses of roughly 20 million U.S. dollars.
Fortunately, we are gratified that the arbitral tribunals have ruled in our
favor, which gives us the opportunity to recover all our economic losses.
Against the backdrop all other international clinical diagnostic producers'
focus on the Chinese market and sincere wishes for long-term cooperation with
China, Abbott U.S.'s behavior shocked all key industry players in China.
Next, Assegai will continue in our quest through another one hundred
arbitration cases or civil actions that have been filed against Abbott U.S.
at CIETAC or local Chinese courts, as we seek further compensation for those
estimated losses amounting to 20 million U.S. dollars."

Liu Jie, +86-10-67191911, +86-10-6710-0992 x182, or liujie at assegai.com.cn